19F MRI to Evaluate Regional Ventilation in Healthy Subjects and Subjects With Cystic Fibrosis

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 1, 2015

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Cystic Fibrosis
Interventions
DRUG

PFP

"* Composition: inhaled PFP, a gaseous contrast agent (79% PFP, 21% O2, pre-mixed, medical grade gas)~* Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.~* Dosage: Two controlled breaths of contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.~* Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred."

Trial Locations (1)

27599

The University of North Carolina at Chapel Hill, Chapel Hill

All Listed Sponsors
lead

University of North Carolina, Chapel Hill

OTHER

NCT03489590 - 19F MRI to Evaluate Regional Ventilation in Healthy Subjects and Subjects With Cystic Fibrosis | Biotech Hunter | Biotech Hunter